Health
Pfizer, GSK Shots for RSV Get Backing for Older Adults
- Older adults should get doctors’ consultation on shots: panel
- Yearly sales of RSV shots seen reaching $10 billion in elders
A nurse prepares an immunization shot in Hialeah, Florida.
Photographer: Joe Raedle/Getty ImagesThis article is for subscribers only.
Shots from Pfizer Inc. and GSK Plc that prevent respiratory syncytial virus received backing from a panel of US public health advisers for use in older adults, paving the way for the preventives to be used in a vulnerable population.
In two separate votes Wednesday, advisers to the Centers for Disease Control and Prevention recommended the shots in people aged 60 and older after consultation with their doctors. CDC Director Rochelle Walensky will decide whether to finalize the recommendations.